October 27, domestic medical device leader Myriad Medical released the "2022 Third Quarterly Report", the data show that in the first three quarters of 2022, the company realized revenue of 23.3 billion yuan, an increase of 20.1% over the same period last year. Realize net profit attributable to shareholders of listed companies 8.1 billion yuan, an increase of 21.6% over the same period of the previous year. The net profit attributable to the first three quarters has exceeded the full-year net profit attributable to the year 2021.
In the third quarter of 2022, the company realized operating income of 7.94 billion yuan, up 20.1% year-on-year, and achieved net attributable profit of 2.81 billion yuan, up 21.4% year-on-year, continuing the trend of stable growth in performance since listing.
For the reasons of performance growth, Myriad Medical said that in the third quarter of 2022, although experiencing the impact of the deterioration of the overseas economic situation, and affected by the recurrence of domestic epidemics, but benefited from the vigorous development of the domestic medical new infrastructure and the continued recovery of the global conventional business, while the company continues to strengthen the internal management, continue to improve the operational efficiency, to achieve the Myriad Medical operating income and net profit of a stable and healthy growth. and healthy growth.
What's worth noting is that Myriad Medical's R&D investment continued to grow at a high rate, amounting to 2.28 billion yuan in the first three quarters, an increase of 27.4 percent year-on-year.
Stable development of three main businesses
Overall, the company's three main businesses have maintained stable performance growth. Firstly, benefiting from the complete recovery of overseas routine reagent business and the bright installed performance of heavyweight instruments, the in vitro diagnostic business achieved high growth during the reporting period, with chemiluminescence leading the growth.
Secondly, the new high-end ultrasound R series and the new mid-range and high-end ultrasound I series were rapidly uploaded to bring breakthroughs in the high-end customer base at home and abroad, which enabled the medical imaging business to accomplish rapid growth during the reporting period.
In addition, through the continuous promotion of new medical infrastructure at home and high-end breakthroughs overseas, the company's life information and support business maintained good growth during the reporting period, with the growth rate increasing quarter-on-quarter, among which the minimally invasive surgery business realized double growth.
In terms of intelligent medical care, Rui Zhilian IT solutions have achieved a cumulative number of signing hospitals up to 320, of which 200 new signing hospitals in the first three quarters; Rui Shadow Cloud + + + imaging cloud service platform has achieved a cumulative total of nearly 2,500 sets of installed, more than 1,100 sets of new installations in the first three quarters; Myriad Intelligent Inspection Laboratory IT solutions to achieve the cumulative total of 110 installed hospitals, of which 75% for the The total number of installed hospitals of Myriad Laboratory IT solutions is 110, of which 75% are tertiary hospitals, with 50 newly installed hospitals in the first three quarters. Myriad Laboratory IT solutions and overall solutions have played a great value in driving the sales of equipment reagents at the regional level, creating a good quality foundation for the mutual recognition of results.
Regionally, with the gradual availability of medical special funds issued by local governments in the first half of the year, the advancement of new medical infrastructure continued to make an important positive contribution to the growth of the domestic market, coupled with the impact of the epidemic on the routine business in the third quarter of the ring improved compared to the second quarter, the domestic market has achieved rapid growth during the reporting period.
Overseas market, although facing a complex and difficult economic situation, but with excellent product quality, strong cost-effective advantage, and further improve the overseas marketing system, Myriad Medical overseas in the breakthrough of high-end customers continue to achieve substantial progress, of which North America and developing countries in the reporting period to complete the rapid growth.
Medicine pointed out that in the future, the company will continue to focus on the three major business areas, and actively expand the seed business with high growth potential, comprehensively strengthen the product R & D innovation, accelerate the change of the international marketing system and deepen the overseas localization of the construction of the multifaceted comprehensive capabilities, to seize the major opportunities of the new domestic healthcare infrastructure and the comprehensive high-end breakthroughs overseas, and to continue to enhance the company's product competitiveness and market penetration; At the same time, we will continue to enhance the quality of internal management and improve operational efficiency, in order to achieve long-term sustainable and healthy growth in operating income and net profit.
The annual performance target is expected to be successfully reached
Earlier this year, Myriad Healthcare launched its first employee stock ownership plan after listing on the A-share market, which involves an amount of about 1 billion yuan and covers nearly 2,700 people. In terms of performance appraisal, Myriad Healthcare took the net profit growth of 20% per year (2022 to 2024) as a condition for unlocking.
From the point of view of the current development situation, Myriad Medical is expected to complete the annual performance target. In addition, in September this year, the National Health Commission launched a policy on the use of subsidized loans for the purchase of medical equipment, also for the solid development of Myriad Medical add another strong agent.
According to the "Notice on the issuance of recommendations and reference materials related to the use of stage-specific financial subsidized interest loans for the acquisition of equipment" issued by the National Health Commission, the notice covers all levels and types of medical and health care institutions, including county-level new coronary pneumonia sentinel hospitals and backup sentinel hospitals and other six major purchasing subjects, as well as a list of specific equipment. The use of financial subsidized loans to update and reconstruct medical equipment in the hospital end of the implementation of the policy has been further clarified.
Up to now, it is expected that the demand for loans related to Myriad Medical products will exceed 20 billion yuan, which greatly enhances the certainty of the company's performance targets. According to the National Health Commission, during the 14th Five-Year Plan period, the state will support the construction of about 120 provincial-level regional medical centers, and Myriad Medical said it will actively participate in the construction plan with high-quality products, complete solutions and after-sales service.
Maintaining high intensity R&D investment
Behind the main business continues to improve, Myriad Medical has always been high intensity R&D investment, products continue to enrich the technology continues to iterate, especially in the high-end products continue to achieve breakthroughs.
In the third quarter of 2022, in the field of in vitro diagnostics, Myriad Medical launched new products such as soluble leukocyte differentiation antigen 14 subtype and interleukin VI chemiluminescent reagents, EU8600 fully automated urinalysis pipeline and supporting reagents. In the medical imaging field, the Company launched new products such as POC Ultra High-End Flatbed Color Ultrasound TEX20, grassroots color ultrasound solution ConsonaN9/8/7/6, professional ophthalmic color ultrasound Determine ZS3Ocular, non-invasive quantitative liver ultrasound instrument Flying Artichoke Hepatus6/5, and the new dual-column fixed DRDigiEye330/350 series. In the field of life information and support, the company launched new products such as TMS30 and TMS60Pro telemetry products, Easy Monitor 2.0 ecosystem, laparoscopic supporting instruments, and disposable ligation clips.
Meanwhile, the company focuses on protecting its independent intellectual property rights through patents. As of September 30, 2022, ***counted 8,349 patents applied for, including 5,958 invention patents; ***counted 3,919 patents authorized, including 1,842 invention patents authorized.
Actively practicing sustainable development strategy
During the reporting period, Myriad Healthcare adhered to the concept of sustainable development and deepened the organic integration of corporate strategy and social responsibility.
The company upgraded and expanded its Environmental, Social and Governance (ESG) Executive Committee, and established six sub-committees around the six major issues of Myriad Healthcare's sustainable development strategy, including standardized corporate governance, innovation-driven future, synergistic development of the business chain, promotion of green development, sustainable workplace, and ****same prosperity, to coordinate and implement the relevant work in all business sectors, and firmly root the concept of sustainable development in the whole value chain of business activities. The concept of sustainable development is firmly rooted in the entire value chain of business activities.
In the field of inclusive healthcare, the Company has continued to strengthen the construction of basic medical facilities and talent training.2022 In September 2022, the Company donated medical equipment valued at more than 51 million yuan to the Heilongjiang Provincial Health and Health Commission through the Heilongjiang Provincial Charity Federation to strengthen the shortcomings of the local medical equipment in the four areas of remote diagnosis and treatment, pre-hospital emergency care, precision medicine and test medicine, and to help enhance the level of medical equipment, remote medical service capacity, and the ability of the medical equipment and test medicine in Heilongjiang Province. This will help improve the level of medical equipment, remote medical service capacity, and the quality of medical services in border areas and grassroots level, and better safeguard the lives and health of the local people.
In terms of industry-academia-research and medical cooperation, in the first three quarters of 2022, the Company ****organized more than 300 international training and academic exchange activities involving product and technology application training and seminars on the latest clinical topics, covering nearly 150,000 people. The company signed a strategic cooperation agreement with Morocco's Hassan I University (LUNIVERSITEacute;HASSAN1er) in July, and the two sides will carry out in-depth cooperation in the areas of joint training of talents, international exchanges and experience sharing, and synergistic development.In September, the company and the Department of Pathological Anatomy at the University of Buenos Aires in Argentina entered into a partnership to provide the college with medical imaging equipment to assist with Classroom demonstration and academic hands-on training. The first Myriad ultrasound training school and pelvic floor research center in South Africa was also inaugurated in September in GrooteSchuurHospital, a top-five public teaching hospital in South Africa, and the two sides will use ultrasound training as a pivot point to strengthen the promotion of special technology and teaching and training.
In addition, Myriad Healthcare is also concerned about public life safety, and is committed to popularizing first aid awareness and using AEDs to enhance first aid skills. in the first three quarters of 2022, the company donated 636 AED devices to its partners, and directly or indirectly promoted first aid training for more than 400,000 participants. As of September 30, 2022, Myriad AEDs have successfully treated a total of 135 patients with cardiac arrest in public **** places in China.
In recent years, Myriad Medical has also actively practiced public welfare. The company joined the China Charity Federation's rescue operation for children with congenital heart disease, providing mobile ultrasound equipment and technical support for congenital heart disease screening activities, and 2022*** screened 120 suspected children with congenital heart disease in Hebei and Shandong. The company's subsidiary Shenzhen Myriad Animal Medical Technology Co., Ltd. also donated animal medical equipment worth 155,000 yuan to the China Small Animal Protection Association's Beijing Too Big Dog Stray Rescue Base.
In the future, Myriad Medical will adhere to the mission of popularizing high-end technology and allowing more people to share quality life care, and will ensure business development while comprehensively upgrading its sustainable development system and fulfilling its social responsibilities in a high-quality manner.
If you want to know more financial news in real time, welcome to follow us.